Video

Dr. Mariette on a Study of Postoperative Mortality After Esophageal and Gastric Cancer Surgery

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer. These findings were presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco.

The objective of this study was to evaluate the impact of age on postoperative mortality according to patient comorbidity in patients who underwent esophageal or gastric cancer surgery between 2010 and 2012 in France (n = 11,196). The 30-day postoperative mortality was compared by age groups, and the consistency across esophageal (n = 3286) and gastric (n = 7910) subgroups and variations between 30-day and 90-day postoperative mortality were investigated.

Overall, the results showed a linear increase in 30-day and 90-day postoperative mortality with increasing age. These findings demonstrate that age and patient comorbidity have a similar and cumulative impact on postoperative mortality after patients are treated with surgery for esophageal and gastric cancer.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center